Cambrex, a small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has unveiled changes to its management team and board of directors.
 
The following appointments and new positions are effective immediately:
 
• Robert Green has been named executive vice president and chief financial officer, succeeding Gregory Sargen, who will depart the company on January 31. Mr. Green joins from General Electric Corporation, where he began his career in 1990 and was most recently CFO of GE Power, a global business unit with $35 billion in revenue operating in 180 countries. In his tenure at GE, Mr. Green served as CFO for eight global business units, including as CFO of GE Healthcare Bio-Sciences, a leading medical diagnostic and life sciences products company.
 
• Shawn Cavanagh has been promoted to president and chief operating officer, and will join the company’s board. He has served as executive vice president and chief operating officer of Cambrex since 2011, having originally joined in 1999, and has been instrumental to the company’s long-term growth and strategic development.
 
• Stephan Haitz has been promoted to president, CDMO sales and marketing. Mr. Haitz joined Cambrex in 2014 and has served as vice president, sales and business development. He previously held various sales and business development roles at Lonza and Solvias AG.
 
In addition, the company’s board of directors will now be comprised of chairman Wayne Hewett; chief executive officer Steven Klosk; president Shawn Cavanagh; Claes Glassell, who will be rejoining the board; Permira partners’ John Coyle and Henry Minello; and Permira principal Laura O’Donnell.